Physician profile
Andrew Ross
NPI 1700140738
$5,469.01
in general payments reported to CMS, 2019-2025
26 companies · $655 in 2025
The $655 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $486 · 2021: $652 · 2022: $798 · 2023: $1,049 · 2024: $1,085 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,688 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,688.29 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,241.71 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $727.47 | 2019-2025 | |
| Janssen Biotech, INC. | $465.05 | 2019-2024 | Tremfya, Stelara, Remicade |
| Leo Pharma INC. | $448.23 | 2019-2025 | Adbry |
| Pfizer INC. | $360.45 | 2019-2025 | |
| Amgen INC. | $325.04 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $291.23 | 2020-2024 | Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $247.48 | 2020-2023 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $229.47 | 2019-2025 | Dupixent, Libtayo |
| Acclarent, INC | $186.81 | 2023 | Trudi Nav Cable |
| Ucb, INC. | $151.98 | 2020-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $136.90 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $136.48 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $112.26 | 2019 | |
| Sanofi-Aventis U.S. LLC | $53.14 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $51.20 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Incyte Corporation | $43.09 | 2023-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.53 | 2023-2025 | Spevigo |
| Strata Skin Sciences, INC. | $40.70 | 2024 | Xtrac |
| Galderma Laboratories, L.P. | $38.32 | 2019-2023 | |
| Dermavant Sciences, INC. | $34.74 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.30 | 2021-2022 | |
| Celgene Corporation | $23.11 | 2019 | |
| Almirall LLC | $23.00 | 2025 | Seysara |
| Arcutis Biotherapeutics, INC. | $16.72 | 2024 | Zoryve |
| Calliditas Therapeutics US INC. | $15.60 | 2025 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.